Characterization and implementation of a diverse simian immunodeficiency virus SIVsm envelope panel in the assessment of neutralizing antibody breadth elicited in rhesus macaques by multimodal vaccines expressing the SIVmac239 envelope

Journal of Virology

Volumn 89, Issue 16, 2015, Pages 8130-8151

  Kilgore, Katie M ^a   Murphy, Megan K ^a,g   Burton, Samantha L ^a   Wetzel, Katherine S ^c   Smith, S Abigail ^a   Xiao, Peng ^a   Reddy, Sharmila ^a   Francella, Nicholas ^c   Sodora, Donald L ^d   Silvestri, Guido ^a,b   Cole, Kelly S ^e   Villinger, Francois ^a,b   Robinson, James E ^f   Pulendran, Bali ^a,b   Hunter, Eric ^a,b   Collman, Ronald G ^c   Amara, Rama R ^a   Derdeyn, Cynthia A ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR LIGAND; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS MAC239; SIMIAN IMMUNODEFICIENCY VIRUS SM; VACCINIA VIRUS; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; CLASSIFICATION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PHYLOGENY; SEQUENCE HOMOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS - SM; VACCINIA VIRUS ANKARA;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE HOMOLOGY, AMINO ACID; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84938151514     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01221-14     Document Type: Article

References (141)

1. McChesney MB, Miller CJ. 2013. New directions for HIV vaccine development from animal models. Curr Opin HIV AIDS 8:376-381. http://dx.doi.org/10.1097/COH.0b013e328363d3a2.
2. Excler JL, Tomaras GD, Russell ND. 2013. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 8:421-431. http://dx.doi.org/10.1097/COH.0b013e3283632c26.
3. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. 2013. Antibodies in HIV-1 vaccine development and therapy. Science 341:1199-1204. http://dx.doi.org/10.1126/science.1241144.
4. Kwong PD, Mascola JR, Nabel GJ. 2013. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13:693-701. http://dx.doi.org/10.1038/nri3516.
5. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012.
6. Johnson WE, Sanford H, Schwall L, Burton DR, Parren PW, Robinson JE, Desrosiers RC. 2003. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol 77:9993-10003. http://dx.doi.org/10.1128/JVI.77.18.9993-10003.2003.
7. Johnson WE, Lifson JD, Lang SM, Johnson RP, Desrosiers RC. 2003. Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus. J Virol 77:375-381. http://dx.doi.org/10.1128/JVI.77.1.375-381.2003.
8. Johnson WE, Morgan J, Reitter J, Puffer BA, Czajak S, Doms RW, Desrosiers RC. 2002. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol 76:2075-2086. http://dx.doi.org/10.1128/jvi.76.5.2075-2086.2002.
9. Means RE, Greenough T, Desrosiers RC. 1997. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol 71:7895-7902.
10. Evans DT, Jing P, Allen TM, O'Connor DH, Horton H, Venham JE, Piekarczyk M, Dzuris J, Dykhuzen M, Mitchen J, Rudersdorf RA, Pauza CD, Sette A, Bontrop RE, DeMars R, Watkins DI. 2000. Definition of five new simian immunodeficiency virus cytotoxic Tlymphocyte epitopes and their restricting major histocompatibility complex class I molecules: evidence for an influence on disease progression. J Virol 74:7400-7410. http://dx.doi.org/10.1128/JVI.74.16.7400-7410.2000.
11. Allen TM, Jing P, Calore B, Horton H, O'Connor DH, Hanke T, Piekarczyk M, Ruddersdorf R, Mothe BR, Emerson C, Wilson N, Lifson JD, Belyakov IM, Berzofsky JA, Wang C, Allison DB, Montefiori DC, Desrosiers RC, Wolinsky S, Kunstman KJ, Altman JD, Sette A, McMichael AJ, Watkins DI. 2002. Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol 76: 10507-10511. http://dx.doi.org/10.1128/JVI.76.20.10507-10511.2002.
12. Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Montefiori DC, Erfle V, Desrosiers RC, Wilson N, Picker LJ, Wolinsky SM, Wang C, Allison DB, Watkins DI. 2002. Immunization of rhesus macaques with a DNA prime/ modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 76:7187-7202. http://dx.doi.org/10.1128/JVI.76.14.7187-7202.2002.
13. Mothe BR, Horton H, Carter DK, Allen TM, Liebl ME, Skinner P, Vogel TU, Fuenger S, Vielhuber K, Rehrauer W, Wilson N, Franchini G, Altman JD, Haase A, Picker LJ, Allison DB, Watkins DI. 2002. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J Virol 76:875-884. http://dx.doi.org/10.1128/JVI.76.2.875-884.2002.
14. Dzuris JL, Sidney J, Horton H, Correa R, Carter D, Chesnut RW, Watkins DI, Sette A. 2001. Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules. J Virol 75:10958-10968. http://dx.doi.org/10.1128/JVI.75.22.10958-10968.2001.
15. Allen TM, Mothe BR, Sidney J, Jing P, Dzuris JL, Liebl ME, Vogel TU, O'Connor DH, Wang X, Wussow MC, Thomson JA, Altman JD, Watkins DI, Sette A. 2001. CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J Virol 75:738-749. http://dx.doi.org/10.1128/JVI.75.2.738-749.2001.
16. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim SY, Yeh WW, Asmal M, Gelman RS, Shen L, Whitney JB, Seoighe C, Lacerda M, Keating S, Norris PJ, Hudgens MG, Gilbert PB, Buzby AP, Mach LV, Zhang J, Balachandran H, Shaw GM, Schmidt SD, Todd JP, Dodson A, Mascola JR, Nabel GJ. 2011. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 3:81ra36. http://dx.doi.org/10.1126/scitranslmed.3002351.
17. Lopker M, Easlick J, Sterrett S, Decker JM, Barbian H, Learn G, Keele BF, Robinson JE, Hahn BH, Shaw GM, Bar KJ. 2013. Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol 87:5477-5492. http://dx.doi.org/10.1128/JVI.03419-12.
18. Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, Todd JP, Buzby AP, Mach LV, Shen L, Seaton KE, Ward BM, Bailer RT, Gottardo R, Gu W, Ferrari G, Alam SM, Denny TN, Montefiori DC, Tomaras GD, Korber BT, Nason MC, Seder RA, Koup RA, Letvin NL, Rao SS, Nabel GJ, Mascola JR. 2014. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 505:502-508. http://dx.doi.org/10.1038/nature12893.
19. Wu F, Ourmanov I, Kuwata T, Goeken R, Brown CR, Buckler-White A, Iyengar R, Plishka R, Aoki ST, Hirsch VM. 2012. Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques. J Virol 86:8835-8847. http://dx.doi.org/10.1128/JVI.00923-12.
20. Reynolds MR, Sacha JB, Weiler AM, Borchardt GJ, Glidden CE, Sheppard NC, Norante FA, Castrovinci PA, Harris JJ, Robertson HT, Friedrich TC, McDermott AB, Wilson NA, Allison DB, Koff WC, Johnson WE, Watkins DI. 2011. The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge. J Virol 85:9637-9640. http://dx.doi.org/10.1128/JVI.05074-11.
21. Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR. 2014. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. J Virol 88:9579-9589. http://dx.doi.org/10.1128/JVI.00975-14.
22. Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, Hirsch V, Villinger F, Chennareddi L, Earl PL, Moss B, Amara RR, Robinson HL. 2011. Prevention of infection by a granulocytemacrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 204:164-173. http://dx.doi.org/10.1093/infdis/jir199.
23. Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, Roychoudhuri R, Shi W, Bao S, Todd JP, Asmal M, Shen L, Donaldson M, Schmidt SD, Gall JG, Pinschewer DD, Letvin NL, Rao S, Mascola JR, Roederer M, Nabel GJ. 2012. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol 86:7760-7770. http://dx.doi.org/10.1128/JVI.00599-12.
24. Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C, von Gegerfelt A, Huang W, Guan Y, Keele BF, Bess JW, Jr, Piatak M, Jr, Lifson JD, Williams WT, Shen X, Tomaras GD, Amara RR, Robinson HL, Johnson W, Broderick KE, Sardesai NY, Venzon DJ, Hirsch VM, Felber BK, Pavlakis GN. 2013. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci U S A 110:2975-2980. http://dx.doi.org/10.1073/pnas.1215393110.
25. Kulkarni V, Rosati M, Jalah R, Ganneru B, Alicea C, Yu L, Guan Y, Labranche C, Montefiori DC, King AD, Valentin A, Pavlakis GN, Felber BK. 2014. DNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques. J Med Primatol 43:329-340. http://dx.doi.org/10.1111/jmp.12123.
26. Kulkarni V, Rosati M, Valentin A, Jalah R, Alicea C, Yu L, Guan Y, Shen X, Tomaras GD, LaBranche C, Montefiori DC, Irene C, Prattipati R, Pinter A, Sullivan SM, Pavlakis GN, Felber BK. 2013. Vaccination with Vaxfectin((R)) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 viremia. Hum Vaccin Immunother 9:2069-2080. http://dx.doi.org/10.4161/hv.25442.
27. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, Sanmiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EM, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93. http://dx.doi.org/10.1038/nature10766.
28. Jia B, Ng SK, DeGottardi MQ, Piatak M, Yuste E, Carville A, Mansfield KG, Li W, Richardson BA, Lifson JD, Evans DT. 2009. Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239. PLoS Pathog 5:e1000272. http://dx.doi.org/10.1371/journal.ppat.1000272.
29. Lai L, Kwa SF, Kozlowski PA, Montefiori DC, Nolen TL, Hudgens MG, Johnson WE, Ferrari G, Hirsch VM, Felber BK, Pavlakis GN, Earl PL, Moss B, Amara RR, Robinson HL. 2012. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 30:1737-1745. http://dx.doi.org/10.1016/j.vaccine.2011.12.026.
30. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439-1452. http://dx.doi.org/10.1128/JVI.02108-09.
31. deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC. 2014. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 88:2489-2507. http://dx.doi.org/10.1128/JVI.02853-13.
32. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. 2014. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28:163-169. http://dx.doi.org/10.1097/QAD.0000000000000106.
33. Derdeyn CA, Moore PL, Morris L. 2014. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses. Curr Opin HIV AIDS 9:210-216. http://dx.doi.org/10.1097/COH.0000000000000057.
34. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR. 2013. Rational HIV immunogen design to target specific germline B cell receptors. Science 340:711-716. http://dx.doi.org/10.1126/science.1234150.
35. Douagi I, Forsell MN, Sundling C, O'Dell S, Feng Y, Dosenovic P, Li Y, Seder R, Lore K, Mascola JR, Wyatt RT, Karlsson Hedestam GB. 2010. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J Virol 84:1683-1695. http://dx.doi.org/10.1128/JVI.01896-09.
36. Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B, Rao SS, Lore K, Mascola JR, Wyatt RT, Douagi I, Karlsson Hedestam GB. 2010. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 207:2003-2017. http://dx.doi.org/10.1084/jem.20100025.
37. Sundling C, O'Dell S, Douagi I, Forsell MN, Morner A, Lore K, Mascola JR, Wyatt RT, Karlsson Hedestam GB. 2010. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simianhuman immunodeficiency virus. J Virol 84:9086-9095. http://dx.doi.org/10.1128/JVI.01015-10.
38. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
39. Li B, Stefano-Cole K, Kuhrt DM, Gordon SN, Else JG, Mulenga J, Allen S, Sodora DL, Silvestri G, Derdeyn CA. 2010. Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies. J Virol 84:6248-6253. http://dx.doi.org/10.1128/JVI.00295-10.
40. Riddick NE, Hermann EA, Loftin LM, Elliott ST, Wey WC, Cervasi B, Taaffe J, Engram JC, Li B, Else JG, Li Y, Hahn BH, Derdeyn CA, Sodora DL, Apetrei C, Paiardini M, Silvestri G, Collman RG. 2010. A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. PLoS Pathog 6:e1001064. http://dx.doi.org/10.1371/journal.ppat.1001064.
41. Elliott ST, Riddick NE, Francella N, Paiardini M, Vanderford TH, Li B, Apetrei C, Sodora DL, Derdeyn CA, Silvestri G, Collman RG. 2012. Cloning and analysis of sooty mangabey alternative coreceptors that support simian immunodeficiency virus SIVsmm entry independently of CCR5. J Virol 86:898-908. http://dx.doi.org/10.1128/JVI.06415-11.
42. + T cell loss is associated with double-negative T cells. J Clin Invest 121:1102-1110. http://dx.doi.org/10.1172/JCI44876.
43. + T cell depletion is not sufficient to induce AIDS in a natural host. J Immunol 179:3047-3056. http://dx.doi.org/10.4049/jimmunol.179.5.3047.
44. Ortiz AM, Klatt NR, Li B, Yi Y, Tabb B, Hao XP, Sternberg L, Lawson B, Carnathan PM, Cramer EM, Engram JC, Little DM, Ryzhova E, Gonzalez-Scarano F, Paiardini M, Ansari AA, Ratcliffe S, Else JG, Brenchley JM, Collman RG, Estes JD, Derdeyn CA, Silvestri G. 2011. Depletion of CD4(+) T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques. J Clin Invest 121:4433-4445. http://dx.doi.org/10.1172/JCI46023.
45. + T cells support production of SIV Env antibodies that enforce CD4-dependent entry and shape tropism in vivo. J Virol 87:9719-9732. http://dx.doi.org/10.1128/JVI.01254-13.
46. Fairman J, Moore J, Lemieux M, Van Rompay K, Geng Y, Warner J, Abel K. 2009. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccin 5:141-150. http://dx.doi.org/10.4161/hv.5.3.6589.
47. Yeh WW, Jaru-Ampornpan P, Nevidomskyte D, Asmal M, Rao SS, Buzby AP, Montefiori DC, Korber BT, Letvin NL. 2009. Partial protection of SIV-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol 83:2686-2696. http://dx.doi.org/10.1128/JVI.02237-08.
48. Schell JB, Rose NF, Bahl K, Diller K, Buonocore L, Hunter M, Marx PA, Gambhira R, Tang H, Montefiori DC, Johnson WE, Rose JK. 2011. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol 85:5764-5772. http://dx.doi.org/10.1128/JVI.00342-11.
49. Cole KS, Alvarez M, Elliott DH, Lam H, Martin E, Chau T, Micken K, Rowles JL, Clements JE, Murphey-Corb M, Montelaro RC, Robinson JE. 2001. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology 290:59-73. http://dx.doi.org/10.1006/viro.2001.1144.
50. Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, Kiviat NB, Sow PS, Georgiev I, Hahn BH, Kwong PD, Robinson JE, Shaw GM. 2012. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 86:947-960. http://dx.doi.org/10.1128/JVI.06155-11.
51. Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker JM, Rowland-Jones SL, Jaye A, Guan Y, Lewis GK, Langedijk JP, Hahn BH, Kwong PD, Robinson JE, Shaw GM. 2012. Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol 86:12115-12128. http://dx.doi.org/10.1128/JVI.01632-12.
52. Robinson JE, Cole KS, Elliott DH, Lam H, Amedee AM, Means R, Desrosiers RC, Clements J, Montelaro RC, Murphey-Corb M. 1998. Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine. AIDS Res Hum Retroviruses 14:1253-1262. http://dx.doi.org/10.1089/aid.1998.14.1253.
53. Robinson JE, Holton D, Pacheco-Morell S, Liu J, McMurdo H. 1990. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res Hum Retroviruses 6:567-579. http://dx.doi.org/10.1089/aid.1990.6.567.
54. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44:1667-1673. http://dx.doi.org/10.1128/AAC.44.6.1667-1673.2000.
55. De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, Debyser Z, Rosenwirth B, Peichl P, Datema R, Thornton D, Skerlj R, Gaul F, Padmanabhan S, Bridger G, Henson G, Abrams M. 1994. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 38:668-674. http://dx.doi.org/10.1128/AAC.38.4.668.
56. Bridger GJ, Skerlj RT, Thornton D, Padmanabhan S, Martellucci SA, Henson GW, Abrams MJ, Yamamoto N, De Vreese K, Pauwels R, De Clercq E. 1995. Synthesis and structure-activity relationships of phenylenebis( methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem 38:366-378.
57. Biswas P, Tambussi G, Lazzarin A. 2007. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin Pharmacother 8:923-933.
58. Emmelkamp JM, Rockstroh JK. 2007. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res 12:409-417.
59. Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD. 2004. Shortterm safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis 189:1075-1083. http://dx.doi.org/10.1086/381707.
60. Reimann KA, Tenner-Racz K, Racz P, Montefiori DC, Yasutomi Y, Lin W, Ransil BJ, Letvin NL. 1994. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol 68:2362-2370.
61. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, Blackwell JL, Derdeyn CA. 2006. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 80:5211-5218. http://dx.doi.org/10.1128/JVI.00201-06.
62. Lynch RM, Rong R, Boliar S, Sethi A, Li B, Mulenga J, Allen S, Robinson JE, Gnanakaran S, Derdeyn CA. 2011. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol 85:905-915. http://dx.doi.org/10.1128/JVI.02006-10.
63. Rong R, Bibollet-Ruche F, Mulenga J, Allen S, Blackwell JL, Derdeyn CA. 2007. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 81:1350-1359. http://dx.doi.org/10.1128/JVI.01839-06.
64. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, Sfakianos JN, Mokili JL, Muldoon M, Mulenga J, Allen S, Hahn BH, Shaw GM, Blackwell JL, Korber BT, Hunter E, Derdeyn CA. 2007. Unique mutational patterns in the envelope {alpha}2 amphipathic helix and acquisition of length in gp120 hyper-variable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 81:5658-5668. http://dx.doi.org/10.1128/JVI.00257-07.
65. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog 5:e1000594. http://dx.doi.org/10.1371/journal.ppat.1000594.
66. Lynch RM, Rong R, Li B, Shen T, Honnen W, Mulenga J, Allen S, Pinter A, Gnanakaran S, Derdeyn CA. 2010. Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. Virology 404:59-70. http://dx.doi.org/10.1016/j.virol.2010.04.010.
67. Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran S, Hunter E, Kong XP, Derdeyn CA. 2013. Viral escape from neutralizing antibodies in early subtypeAHIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 9:e1003173. http://dx.doi.org/10.1371/journal.ppat.1003173.
68. Apetrei C, Gautam R, Sumpter B, Carter AC, Gaufin T, Staprans SI, Else J, Barnes M, Cao R, Jr, Garg S, Milush JM, Sodora DL, Pandrea I, Silvestri G. 2007. Virus subtype-specific features of natural simian immunodeficiency virus SIVsmm infection in sooty mangabeys. J Virol 81:7913-7923. http://dx.doi.org/10.1128/JVI.00281-07.
69. Apetrei C, Kaur A, Lerche NW, Metzger M, Pandrea I, Hardcastle J, Falkenstein S, Bohm R, Koehler J, Traina-Dorge V, Williams T, Staprans S, Plauche G, Veazey RS, McClure H, Lackner AA, Gormus B, Robertson DL, Marx PA. 2005. Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. J Virol 79:8991-9005. http://dx.doi.org/10.1128/JVI.79.14.8991-9005.2005.
70. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, Abdool Karim SS, Williamson C, Morris L. 2008. The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 82:1860-1869. http://dx.doi.org/10.1128/JVI.02187-07.
71. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. http://dx.doi.org/10.1038/nature01470.
72. Decker JM, Bibollet-Ruche F, Wei XP, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw GM. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201:1-14. http://dx.doi.org/10.1084/jem.20042514.
73. Reeves JD, Hibbitts S, Simmons G, McKnight A, Azevedo-Pereira JM, Moniz-Pereira J, Clapham PR. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 73:7795-7804.
74. O'Connell O, Repik A, Reeves JD, Gonzalez-Perez MP, Quitadamo B, Anton ED, Duenas-Decamp M, Peters P, Lin R, Zolla-Pazner S, Corti D, Wallace A, Wang S, Kong XP, Lu S, Clapham PR. 2013. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. J Virol 87:187-198. http://dx.doi.org/10.1128/JVI.01834-12.
75. Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol 85:8954-8967. http://dx.doi.org/10.1128/JVI.00754-11.
76. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, Garcia-Sastre A, Compans R, Pulendran B. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543-547. http://dx.doi.org/10.1038/nature09737.
77. Manrique J, Piatak M, Lauer W, Johnson W, Mansfield K, Lifson J, Desrosiers R. 2013. Influence of mismatch of Env sequences on vaccine protection by live attenuated simian immunodeficiency virus. J Virol 87:7246-7254. http://dx.doi.org/10.1128/JVI.00798-13.
78. Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, Robinson J, Wyand MS, Desrosiers RC, Montelaro RC. 1997. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 71:5069-5079.
79. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin Vaccine Immunol 17:1055-1065. http://dx.doi.org/10.1128/CVI.00131-10.
80. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275-1286. http://dx.doi.org/10.1056/NEJMoa1113425.
81. Weiss RA, Clapham PR, Cheingsong-Popov R, Dalgleish AG, Carne CA, Weller IV, Tedder RS. 1985. Neutralization of human Tlymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 316:69-72. http://dx.doi.org/10.1038/316069a0.
82. Nara PL, Robey WG, Pyle SW, Hatch WC, Dunlop NM, Bess JW, Jr, Kelliher JC, Arthur LO, Fischinger PJ. 1988. Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol 62:2622-2628.
83. Cheng-Mayer C, Homsy J, Evans LA, Levy JA. 1988. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci U S A 85:2815-2819. http://dx.doi.org/10.1073/pnas.85.8.2815.
84. Golding H, D'Souza MP, Bradac J, Mathieson B, Fast P. 1994. Neutralization of HIV-1. AIDS Res Hum Retroviruses 10:633-643. http://dx.doi.org/10.1089/aid.1994.10.633.
85. Matthews TJ. 1994. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 10:631-632. http://dx.doi.org/10.1089/aid.1994.10.631.
86. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173:340-348.
87. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 2000. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des 8:1329-1339. http://dx.doi.org/10.1016/S0969-2126(00)00547-5.
88. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682. http://dx.doi.org/10.1038/nature01188.
89. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC. 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79:10103-10107. http://dx.doi.org/10.1128/JVI.79.16.10103-10107.2005.
90. Seaman MS, Leblanc DF, Grandpre LE, Bartman MT, Montefiori DC, Letvin NL, Mascola JR. 2007. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single-or multiclade HIV-1 envelope immunogens. Virology 367:175-186. http://dx.doi.org/10.1016/j.virol.2007.05.024.
91. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccineelicited neutralizing antibodies. J Virol 79:10108-10125. http://dx.doi.org/10.1128/JVI.79.16.10108-10125.2005.
92. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa. J Virol 80:11776-11790. http://dx.doi.org/10.1128/JVI.01730-06.
93. Shaw GM, Hunter E. 2012. HIV transmission. Cold Spring Harbor Perspect Med 2:a006965. http://dx.doi.org/10.1101/cshperspect.a006965.
94. Esparza J. 2013. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 31:3502-3518. http://dx.doi.org/10.1016/j.vaccine.2013.05.018.
95. Derdeyn CA. 2014. Humoral immune responses in SIV infection of sooty mangabeys: implications for HIV-1 pathogenesis and vaccine design. In Silvestri G, Ansari AA (ed), Natural hosts of SIV. Academic Press/Elsevier, Waltham, MA.
96. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR. 1989. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 339:389-392. http://dx.doi.org/10.1038/339389a0.
97. Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, Greene BM, Sharp PM, Shaw GM, Hahn BH. 1992. Human infection by genetically diverse SIVSM-related HIV-2 in West Africa. Nature 358: 495-499. http://dx.doi.org/10.1038/358495a0.
98. Beddows S, Louisirirotchanakul S, Cheingsong-Popov R, Easterbrook PJ, Simmonds P, Weber J. 1998. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol 79(Pt 1):77-82.
99. Spenlehauer C, Saragosti S, Fleury HJ, Kirn A, Aubertin AM, Moog C. 1998. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. J Virol 72:9855-9864.
100. York J, Follis KE, Trahey M, Nyambi PN, Zolla-Pazner S, Nunberg JH. 2001. Antibody binding and neutralization of primary and T-cell lineadapted isolates of human immunodeficiency virus type 1. J Virol 75: 2741-2752. http://dx.doi.org/10.1128/JVI.75.6.2741-2752.2001.
101. Fischer W, Apetrei C, Santiago ML, Li Y, Gautam R, Pandrea I, Shaw GM, Hahn BH, Letvin NL, Nabel GJ, Korber BT. 2012. Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. J Virol 86:13217-13231. http://dx.doi.org/10.1128/JVI.01862-12.
102. Rasmussen RA, Ong H, Song R, Chenine AL, Ayash-Rashkovsky M, Hu SL, Polacino P, Else JG, November FJ, Ruprecht RM, Clade C Program Project. 2007. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS 21:1841-1848. http://dx.doi.org/10.1097/QAD.0b013e32828684ea.
103. Fouda GG, Amos JD, Wilks AB, Pollara J, Ray CA, Chand A, Kunz EL, Liebl BE, Whitaker K, Carville A, Smith S, Colvin L, Pickup DJ, Staats HF, Overman G, Eutsey-Lloyd K, Parks R, Chen H, Labranche C, Barnett S, Tomaras GD, Ferrari G, Montefiori DC, Liao HX, Letvin NL, Haynes BF, Permar SR. 2013. Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. J Virol 87:6986-6999. http://dx.doi.org/10.1128/JVI.00528-13.
104. Quinnan GV, Jr, Zhang P, Dong M, Chen H, Feng YR, Lewis M, Broder CC. 2013. Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins. PLoS One 8:e59803. http://dx.doi.org/10.1371/journal.pone.0059803.
105. Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ. 2011. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 29:1421-1430. http://dx.doi.org/10.1016/j.vaccine.2010.12.034.
106. Chakrabarti BK, Feng Y, Sharma SK, McKee K, Karlsson Hedestam GB, Labranche CC, Montefiori DC, Mascola JR, Wyatt RT. 2013. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. J Virol 87:13239-13251. http://dx.doi.org/10.1128/JVI.01247-13.
107. Santra S, Muldoon M, Watson S, Buzby A, Balachandran H, Carlson KR, Mach L, Kong WP, McKee K, Yang ZY, Rao SS, Mascola JR, Nabel GJ, Korber BT, Letvin NL. 2012. Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 428:121-127. http://dx.doi.org/10.1016/j.virol.2012.03.012.
108. Yin J, Dai A, Lecureux J, Arango T, Kutzler MA, Yan J, Lewis MG, Khan A, Sardesai NY, Montefiore D, Ruprecht R, Weiner DB, Boyer JD. 2011. High antibody and cellular responses induced to HIV-1 cladeC envelope following DNA vaccines delivered by electroporation. Vaccine 29:6763-6770. http://dx.doi.org/10.1016/j.vaccine.2010.12.055.
109. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206:431-441. http://dx.doi.org/10.1093/infdis/jis367.
110. McCormack S, Tilzey A, Carmichael A, Gotch F, Kepple J, Newberry A, Jones G, Lister S, Beddows S, Cheingsong R, Rees A, Babiker A, Banatvala J, Bruck C, Darbyshire J, Tyrrell D, Van Hoecke C, Weber J. 2000. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18:1166-1177. http://dx.doi.org/10.1016/S0264-410X(99)00388-6.
111. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L. 2013. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 210: 655-663. http://dx.doi.org/10.1084/jem.20122824.
112. Alam SM, Dennison SM, Aussedat B, Vohra Y, Park PK, Fernandez-Tejada A, Stewart S, Jaeger FH, Anasti K, Blinn JH, Kepler TB, Bonsignori M, Liao HX, Sodroski JG, Danishefsky SJ, Haynes BF. 2013. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad SciUSA 110:18214-18219. http://dx.doi.org/10.1073/pnas.1317855110.
113. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang ZY, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF. 2013. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38:176-186. http://dx.doi.org/10.1016/j.immuni.2012.11.011.
114. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, Kincer LP, Treurnicht FK, Arney L, Ojeda S, Zhang M, Keys J, Potter EL, Chu H, Moore P, Salazar MG, Iyer S, Jabara C, Kirchherr J, Mapanje C, Ngandu N, Seoighe C, Hoffman I, Gao F, Tang Y, Labranche C, Lee B, Saville A, Vermeulen M, Fiscus S, Morris L, Karim SA, Haynes BF, Shaw GM, Korber BT, Hahn BH, Cohen MS, Montefiori D, Williamson C, Swanstrom R. 2013. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol 87:7218-7233. http://dx.doi.org/10.1128/JVI.03577-12.
115. Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, Regier D, Sehgal P, Daniel M, King N, Desrosiers RC. 1990. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248:1109-1112. http://dx.doi.org/10.1126/science.2160735.
116. Luciw PA, Shaw KE, Unger RE, Planelles V, Stout MW, Lackner JE, Pratt-Lowe E, Leung NJ, Banapour B, Marthas ML. 1992. Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS ResHumRetroviruses 8:395-402. http://dx.doi.org/10.1089/aid.1992.8.395.
117. Marthas ML, Ramos RA, Lohman BL, Van Rompay KK, Unger RE, Miller CJ, Banapour B, Pedersen NC, Luciw PA. 1993. Viral determinants of simian immunodeficiency virus (SIV) virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac. J Virol 67:6047-6055.
118. Lackner AA, Vogel P, Ramos RA, Kluge JD, Marthas M. 1994. Early events in tissues during infection with pathogenic (SIVmac239) and nonpathogenic (SIVmac1A11) molecular clones of simian immunodeficiency virus. Am J Pathol 145:428-439.
119. Puffer BA, Pohlmann S, Edinger AL, Carlin D, Sanchez MD, Reitter J, Watry DD, Fox HS, Desrosiers RC, Doms RW. 2002. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 76:2595-2605. http://dx.doi.org/10.1128/JVI.76.6.2595-2605.2002.
120. Zhuge W, Jia F, Adany I, Narayan O, Stephens EB. 1997. Plasmas from lymphocyte-and macrophage-tropic SIVmac-infected macaques have antibodies with a broader spectrum of virus neutralization activity in macrophage versus lymphocyte cultures. Virology 227:24-33. http://dx.doi.org/10.1006/viro.1996.8300.
121. Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T, Desrosiers RC. 2001. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. J Virol 75:3903-3915. http://dx.doi.org/10.1128/JVI.75.8.3903-3915.2001.
122. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S. 2010. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 6:e1001249. http://dx.doi.org/10.1371/journal.ppat.1001249.
123. White TA, Bartesaghi A, Borgnia MJ, de la Cruz MJ, Nandwani R, Hoxie JA, Bess JW, Lifson JD, Milne JL, Subramaniam S. 2011. Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. J Virol 85:12114-12123. http://dx.doi.org/10.1128/JVI.05297-11.
124. McDermott AB, Mitchen J, Piaskowski S, De Souza I, Yant LJ, Stephany J, Furlott J, Watkins DI. 2004. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol 78:3140-3144. http://dx.doi.org/10.1128/JVI.78.6.3140-3144.2004.
125. Stone M, Keele BF, Ma ZM, Bailes E, Dutra J, Hahn BH, Shaw GM, Miller CJ. 2010. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 84:7083-7095. http://dx.doi.org/10.1128/JVI.00481-10.
126. Hirsch VM, Zack PM, Vogel AP, Johnson PR. 1991. Simian immunodeficiency virus infection of macaques: end-stage disease is characterized by widespread distribution of proviral DNA in tissues. J Infect Dis 163: 976-988. http://dx.doi.org/10.1093/infdis/163.5.976.
127. Goldstein S, Elkins WR, London WT, Hahn A, Goeken R, Martin JE, Hirsch VM. 1994. Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells. JMedPrimatol 23:75-82. http://dx.doi.org/10.1111/j.1600-0684.1994.tb00105.x.
128. Dehghani H, Puffer BA, Doms RW, Hirsch VM. 2003. Unique pattern of convergent envelope evolution in simian immunodeficiency virusinfected rapid progressor macaques: association with CD4-independent usage of CCR5. J Virol 77:6405-6418. http://dx.doi.org/10.1128/JVI.77.11.6405-6418.2003.
129. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022. http://dx.doi.org/10.1126/science.1093137.
130. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA, Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson AS, Bhattacharya T, Korber BT, Hahn BH, Shaw GM. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad SciUSA105:7552-7557. http://dx.doi.org/10.1073/pnas.0802203105.
131. Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, Hunter E, Derdeyn CA, Collman RG. 2009. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol 83:8208-8220. http://dx.doi.org/10.1128/JVI.00296-09.
132. Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E. 2010. Donor and recipient Envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. J Virol 84:4100-4104. http://dx.doi.org/10.1128/JVI.02068-09.
133. Kirchhoff F, Morrison HG, Murray MG, Rennert P, Desrosiers RC. 1994. SIVmac expressing hybrid envelope proteins containing HIV-1 V3 and/or C4 sequences is not competent for replication. AIDS Res Hum Retroviruses 10:309-313. http://dx.doi.org/10.1089/aid.1994.10.309.
134. Finzi A, Pacheco B, Xiang SH, Pancera M, Herschhorn A, Wang L, Zeng X, Desormeaux A, Kwong PD, Sodroski J. 2012. Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association andCD4binding. J Virol 86:8974-8986. http://dx.doi.org/10.1128/JVI.01076-12.
135. Edinger AL, Amedee A, Miller K, Doranz BJ, Endres M, Sharron M, Samson M, Lu ZH, Clements JE, Murphey-Corb M, Peiper SC, Parmentier M, Broder CC, Doms RW. 1997. Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci U S A 94:4005-4010. http://dx.doi.org/10.1073/pnas.94.8.4005.
136. Edinger AL, Mankowski JL, Doranz BJ, Margulies BJ, Lee B, Rucker J, Sharron M, Hoffman TL, Berson JF, Zink MC, Hirsch VM, Clements JE, Doms RW. 1997. CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci U S A 94:14742-14747. http://dx.doi.org/10.1073/pnas.94.26.14742.
137. Martin KA, Wyatt R, Farzan M, Choe H, Marcon L, Desjardins E, Robinson J, Sodroski J, Gerard C, Gerard NP. 1997. CD4-independent binding of SIV gp120 to rhesus CCR5. Science 278:1470-1473. http://dx.doi.org/10.1126/science.278.5342.1470.
138. Mori K, Rosenzweig M, Desrosiers RC. 2000. Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. J Virol 74:10852-10859. http://dx.doi.org/10.1128/JVI.74.22.10852-10859.2000.
139. Pohlmann S, Davis C, Meister S, Leslie GJ, Otto C, Reeves JD, Puffer BA, Papkalla A, Krumbiegel M, Marzi A, Lorenz S, Munch J, Doms RW, Kirchhoff F. 2004. Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors. J Virol 78: 3223-3232. http://dx.doi.org/10.1128/JVI.78.7.3223-3232.2004.
140. Puffer BA, Altamura LA, Pierson TC, Doms RW. 2004. Determinants within gp120 and gp41 contribute to CD4 independence of SIV Envs. Virology 327:16-25. http://dx.doi.org/10.1016/j.virol.2004.03.016.
141. Schenten D, Marcon L, Karlsson GB, Parolin C, Kodama T, Gerard N, Sodroski J. 1999. Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells. J Virol 73:5373-5380.